MedTrace Logo

A Study to Evaluate COR-1004 in Adult Volunteers.

NCT07229118 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-28

No results posted yet for this study

Summary

This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug. The study will look at how different dose levels of COR-1004 affect the levels of LDL cholesterol (often called "bad" cholesterol) in the blood. The study will enroll otherwise healthy volunteers who have LDL cholesterol of 100 mg/dl or higher but are not currently taking any cholesterol-lowering medicines.

The main purpose of this study is to test a new drug, COR-1004. Researchers want to find out:

* If the drug is safe and if people have any side effects.
* The highest dose that can be given without causing serious side effects.
* How the body processes the drug.
* How the drug affects the amount of "bad" cholesterol in the blood.

This is an early-phase study. The information learned will help decide if COR-1004 should be tested in larger studies in the future.

To be in this study, you must:

* Be generally healthy.
* Have an LDL ("bad") cholesterol level of 100 mg/dL or higher.
* Not currently be taking any medications to lower your cholesterol.

If you decide to join the study, you will be placed into a group by chance, like flipping a coin. This is called "randomization." In each group, most people (8 out of 10) will get a single injection of the study drug (COR-1004). The other people (2 out of 10) will get a placebo. A placebo looks just like the study drug but has no active medicine in it. Using a placebo helps researchers understand the true effects of the real drug.

This is a "double-blind" study, which means that neither you nor the study doctor will know if you are getting the study drug or the placebo.

The study will test different dose levels of COR-1004. It will start with a low dose and, only if it is proven to be safe, will a new group of participants be given a slightly higher dose. To be extra safe, the first two people in each new dose group will be watched for 24 hours before the other eight people in that group get their injection.

After the injection, you will need to visit the study clinic several times over the next year for follow-up. These visits will include:

* Answering questions about your health.
* Physical exams.
* Blood tests to check your safety and your cholesterol levels.

A special group of experts, called a Safety Review Committee, will carefully watch over the study to protect all participants.

Your active participation in the study, including follow-up visits, will last for about 12 months after you receive the single injection.

Because COR-1004 is a new drug, there may be risks that are not yet known. The study staff will explain all the known risks to you before you agree to participate. Known risks may include discomfort at the injection site, like redness, swelling, or pain. The study team will monitor you very closely for any side effects throughout the study.

Conditions

Interventions

DRUG

COR-1004

COR-1004 administered by subcutaneous (SC) injection

DRUG

Placebo

Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.

Sponsors & Collaborators

  • Corsera Health

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-28
Primary Completion
2026-07-31
Completion
2027-11-30

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07229118 on ClinicalTrials.gov